Mazur Piotr, Kosiński Sylweriusz, Podsiadło Paweł, Jarosz Anna, Przybylski Roman, Litiwnowicz Radosław, Piątek Jacek, Konstanty-Kalandyk Janusz, Gałązkowski Robert, Darocha Tomasz
Department of Cardiovascular Surgery and Transplantology, John Paul II Hospital, Cracow, Poland.
Institute of Cardiology, Jagiellonian University Medical College, Cracow, Poland.
Ann Cardiothorac Surg. 2019 Jan;8(1):137-142. doi: 10.21037/acs.2018.10.12.
The incidence of accidental hypothermia (core temperature ≤35 °C) is difficult to estimate, as the affected population is heterogeneous. Both temperature and clinical presentation should be considered while determining severity, which is difficult in a prehospital setting. Extracorporeal rewarming is advocated for all Swiss Staging System class IV (hypothermic cardiac arrest) and class III (hypothermic cardiac instability) patients. Veno-arterial extracorporeal membrane oxygenation (ECMO) is the method of choice, as it not only allows a gradual, controlled increase of core body temperature, but also provides respiratory and hemodynamic support during the unstable period of rewarming and reperfusion. This poses difficulties with the coordination of patient management, as usually only cardiac referral centers can deliver such advanced treatment. Further special considerations apply to subgroups of patients, including drowning or avalanche victims. The principle of ECMO implantation in severely hypothermic patients is no different from any other indication, although establishing vascular access in a timely manner during ongoing resuscitation and maintaining adequate flow may require modification of the operating technique, as well as aggressive fluid resuscitation. Further studies are needed in order to determine the optimal rewarming rate and flow that would favor brain and lung protection. Recent analysis shows an overall survival rate of 40.3%, while additional prognostic factors are being sought for determining those patients in whom the treatment is futile. New cannulas, along with ready-to-use ECMO sets, are being developed that would enable easy, safe and efficient out-reach ECMO implantation, thus shortening resuscitation times. Moreover, national guidelines for the management of accidental hypothermia are needed in order that all patients that would benefit from extracorporeal rewarming would be provided with such treatment. In this perspective article, we discuss burning problems in ECMO therapy in hypothermic patients, outlining the important research goals to improve the outcomes.
意外低温(核心体温≤35°C)的发病率难以估计,因为受影响人群具有异质性。在确定严重程度时应同时考虑体温和临床表现,而这在院前环境中很难做到。对于所有瑞士分期系统IV级(低温性心脏骤停)和III级(低温性心脏不稳定)的患者,主张采用体外复温。静脉-动脉体外膜肺氧合(ECMO)是首选方法,因为它不仅能使核心体温逐渐、可控地升高,还能在复温和再灌注的不稳定期提供呼吸和血流动力学支持。这给患者管理的协调带来了困难,因为通常只有心脏转诊中心才能提供这种高级治疗。对于包括溺水或雪崩受害者在内的患者亚组,还需要进一步的特殊考虑。在严重低温患者中植入ECMO的原则与其他任何适应症并无不同,尽管在持续复苏过程中及时建立血管通路并维持足够的血流量可能需要调整操作技术以及积极的液体复苏。需要进一步研究以确定有利于脑和肺保护的最佳复温速率和血流量。最近的分析显示总体生存率为40.3%,同时正在寻找其他预后因素以确定哪些患者的治疗是无效的。正在开发新的插管以及即用型ECMO套件,这将使ECMO的植入简便、安全且高效,从而缩短复苏时间。此外,需要制定意外低温管理的国家指南,以便所有能从体外复温中受益的患者都能得到这种治疗。在这篇观点文章中,我们讨论了低温患者ECMO治疗中的紧迫问题,概述了改善治疗结果的重要研究目标。